NEW!

Wednesday, April 20
Scientific Platform Sessions
6:30 a.m.–8:30 a.m. Scientific Platform Sessions
S36: Update in Muscle
Disorders
6:30 a.m. S36.001
Anti-cN1A Autoantibody Seropositivity
Is Associated with Increased Mortality
Risk in Inclusion Body Myositis —James
Lilleker, Anke Rietveld (joint first author),
Umesh Badrising, Olivier Benveniste,
Karina Gheorghe, Michael Hanna, Megan
Herbert, David Hilton-Jones, Janine
Lamb, Bryan Lecky, Ingrid Lundberg, Pedro
Machado, Kubéraka Mariampillai, James
Miller, Matt Parton, Maikel Peeters,
Stephen Pye, Mark Roberts, Sabrina
Sacconi, Christiaan Saris, Robert Cooper,
Ger Pruijn, Hector Chinoy, Baziel van
Engelen
6:45 a.m. S36.002
Limb Girdle Muscular Dystrophy Due
to Calpainopathy Also Exists in a
Dominantly Inherited Form —John
Vissing, Rita Barresi, Nanna Witting,
Marijke van Ghelue, Laurence Bindoff,
Straub Volker, Hanns Lochmuller, Christoph
Wahl, Christoffer Jonsrud, Morten Duno
7:00 a.m. S36.003
Disease-Specific Splicing Changes
Are Seen in Children with Congenital
Myotonic Dystrophy —Donald
McCorquodale, Katie Mayne, Diane Dunn,
Brith Otterud, Nicholas Johnson, Robert
Weiss
7:15 a.m. S36.004
A Novel Glycogenin-1 Gene Mutation
in a Family with Late-onset Proximal
Myopathy —Corrado Angelini, Marina
Fanin, Vincenzo Nigro, Annalaura Torella,
Marco Savarese
7:30 a.m. S36.005
Silencing of Myotonic Dystrophy
Protein Kinase (DMPK) Does Not
Affect Cardiac or Muscle Function in
Mice —Samuel Carrell, Ellie Carrell, David
Auerbach, Sanjay Pandey, Frank Bennett,
Robert Dirksen, Charles Thornton
7:45 a.m. S36.006
Electrical Impedance Myography Is
Reliable and Correlates to Measures
of Facioscapulohumeral Muscular
Dystrophy Disease Severity —Jeffrey
Statland, Chad Heatwole, Katy Eichinger,
Nuran Dilek, William Martens, Alrabi Tawil
8:00 a.m. S36.007
Exercise Training Normalizes
Mitochondrial Function in Myopathies
Due to Heteroplasmic Mitochondrial
DNA (mtDNA) Mutations —Ronald
Haller
8:15 a.m. S36.008
Revisiting the Clinical, Histochemical
and Molecular Spectrum of Adult-
Onset AdPEO Associated with the
C10Orf2 (PEO1) Mutation —Grainne
Gorman, Kate Craig, Carl Fratter, Yi
Shiau Ng, Andrew Purvis, Robert Field,
Emma Blakely, Joanna Poulton, Robert
McFarland, Doug Turnbull, Robert Taylor
S37: Risk Factors for Multiple
Sclerosis
6:30 a.m. S37.001
Dietary Intake of Sodium and Other
Minerals and the Risk of Multiple
Sclerosis —Marianna Cortese, Tanuja
Chitnis, Alberto Ascherio, Kassandra
Munger
6:45 a.m. S37.002
Increased Sodium Intake Is Not
Associated with MS Activity or
Progression in BENEFIT —Kathryn
Fitzgerald, Kassandra Munger, Mark
Freedman, Hans Hartung, Xavier
Montalban, Gilles Edan, Frederik Barkhof,
Ernst-Wilhelm Radue, Ludwig Kappos,
Gustavo Suarez, Alberto Ascherio
7:00 a.m. S37.003
Smoking Cessation Decelerates Brain
Volume Loss in Patients with Multiple
Sclerosis —Navid Seraji-Bozorgzad,
Fen Bao, Sara Razmjou, Christina Caon,
Alexandros Tselis, Carla Santiago
Martinez, Imad Zak, Evanthia Bernitsas,
Omar Khan
7:15 a.m. S37.004
Physical Comorbidities Are Associated
with an Increased Risk of Psychiatric
Comorbidity in Multiple Sclerosis —
Ruth-Ann Marrie, Scott Patten, Jamie
Greenfield, Helen Tremlett, Christina
Wolfson, Sharon Warren, Larry Svenson,
Nathalie Jette, John Fisk
7:30 a.m. S37.005
Multiple Sclerosis Lesions Show
Perturbations in Cerebral Microbiota —
William Branton, Jian Lu, Michael Surette,
Robert Holt, John Lind, Jon Laman,
Christopher Power
7:45 a.m. S37.006
Novel Multiple Sclerosis Genetic Risk
Factors Are Involved in Epigenetic
Regulation —Dorothea Buck, Till
Andlauer, Antonios Bayas, Klaus Berger,
Achim Berthele, Elisabeth Binder, Theresa
Dankwoski, Andre Franke, Ralf Gold, Stefan
Herms, Georg Homuth, Karl-Heinz Joeckel,
Tim Kacprowski, Bernd Kieseier, Tania
Kuempfel, Matthias Laudes, Wolfgang
Lieb, Volker Limmroth, Ralf Linker, Susanne
Moebus, Martina Mueller-Nurasyid,
Antonella Mulas, Markus Noethen,
Friedemann Paul, Martin Stangel, Jan-
Patrick Stellmann, Konstantin Strauch,
Bjorn Tackenberg, Florian Then Bergh,
Hayrettin Tumani, Frank Weber, Peter
Weber, Heinz Wiendl, Brigitte Wildemann,
Uwe Zettl, Andreas Ziegler, Ulf Ziemann,
Frauke Zipp, Francesco Cucca, Bertram
Müller-Myhsok, Bernhard Hemmer
8:00 a.m. S37.007
Grey Matter Lesion Signature of
Multiple Sclerosis —Jun-ichi Satoh,
Yoshihiro Kino
8:15 a.m. S37.008
Multiple Sclerosis Clinical
Characteristics in Molecularly-
Defined Patient Populations —Ahmed
Enayetallah, Raghavendra Hosur, Richard
Ransohoff, Jaya Goyal
S38: General Neurology:
Therapeutics
6:30 a.m. S38.001
Edaravone, a Free Radical Scavenger,
Delays Symptomatic and Pathological
Progression of Wobbler Mouse Motor
Neuron Disease —Ken Ikeda, Yasuo
Iwasaki
6:45 a.m. S38.002
Hematopoietic Stem Cell
Transplantation in Late-Onset Krabbe
Disease Halts Demyelination and
Axonal Loss: A 4-Year Longitudinal
Case Study —Cornelia Laule, Elham
Shahinfard, Burkhard Mӓdler, Irene
Vavasour, Jing Zhang, Ritu Aul, David Li,
Alex MacKay, Sandra Sirrs
7:00 a.m. S38.003
Phase 2 Open-Label Extension Study
(OLE) of Patisiran, an Investigational
RNAi Therapeutic for Familial Amyloid
Polyneuropathy (FAP)—David Adams,
Teresa Coelho, Isabel Conceicao, Marcia
Waddington-Cruz, Hartmut Schmidt, Juan
Buades, Josep Campistol, Jean Pouget,
John Berk, Rick Falzone, Lindsey White,
Brian Bettencourt, Jeff Cehelsky, Sara
Nochur, Akshay Vaishnaw, Kirsten Gruis,
Jared Gollob, Ole Suhr
7:15 a.m. S38.004
Functional and Imaging Studies of
the Selective Inhibitor of Nuclear
Export (SINE) Compound KPT-350 in
a Clinically Relevant Murine Model of
Closed Head Injury (CHI) —Claire Drolen,
Haichen Wang, Talaignair Venkatraman,
Chuan Fang, Yanli Tan, Sharon Tamir,
Sharon Shacham, Christopher Lascola,
Daniel Laskowitz
7:30 a.m. S38.005
Phase 1 Safety and Pharmacokinetics
of the Novel Enzyme Replacement
Therapy NeoGAA in Treatment-Naïve
and Alglucosidase Alfa-Treated Late-
Onset Pompe Disease Patients —Jaya
Trivedi, Ans Van Der Ploeg, Richard Barohn,
Barry Byrne, Claude Desnuelle, Ozlem
Goker-Alpan, Shafeeq Ladha, Pascal
Laforet, Eugen Mengel, Alan Pestronk,
Jean Pouget, Benedikt Schoser, Volker
Straub, Philip Van Damme, John Vissing,
Peter Young, Raheel Shafi, Kerry Culm-
Merdek, Gerard Short, Loren Pena, and the
NeoGAA Investigator Group
7:45 a.m. S38.006
Phase 1 Exploratory Efficacy of the
Novel Enzyme Replacement Therapy
NeoGAA in Treatment-Naïve and
Alglucosidase Alfa-Treated Late-Onset
Pompe Disease Patients —Loren Pena,
Richard Barohn, Barry Byrne, Claude
Desnuelle, Ozlem Goker-Alpan, Shafeeq
Ladha, Pascal Laforet, Eugen Mengel, Alan
Pestronk, Jean Pouget, Benedikt Schoser,
Volker Straub, Jaya Trivedi, Philip Van
Damme, John Vissing, Peter Young, Beth
Thurberg, Kerry Culm-Merdek, Gerard
Short, Ans van der Ploeg, and the NeoGAA
Investigator Group
8:00 a.m. S38.007
The Effect of Bolus Volume
and Mechanical Forces on the
Biodistribution of ASOs Following
Lumbar Intrathecal Administration in
Cynomolgus Monkeys —Daniel Wolf,
Jenna Sullivan, Curt Mazur, Eric Swayze,
Berit Powers, Jack Hoppin, Ajay Verma
8:15 a.m. S38.008
Kinetics of ASO Distribution and
Pharmacodynamics in the CNS After
an Intrathecal Bolus Dose in Rat —Eric
Swayze, Berit Powers, Fredrik Kamme,
Curt Mazur, Daniel Wolf, Jenna Sullivan,
Ajay Verma
$ A registration fee is required
L The program is one of the
AAN Leadership University sessions
S The course is part of a Subspecialty in Focus track
I The program is one of the I Talk sessions
Learning
Lab
Excitement of
Discovery
Health
& Wellness
Real World
of Neurology
The program is part of the
Experiential Learning Area sessions
110 2016 AAN Annual Meeting Abstract Listing